Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937579 | 1.00 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27589544 | 0.93 | GRIN1 (0.35) | GRIN1GRIN2A | |
| SCHEMBL3332058 | 0.93 | GRIN1 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24702209 | 0.91 | GRIN1 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17327469 | 0.91 | GRIN1 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16219931 | 0.91 | GRIN1 (0.36) | GRIN1GRIN2A | |
| SCHEMBL19288763 | 0.89 | GRIN1 (0.38) | GRIN1GRIN2A | |
| SCHEMBL22176939 | 0.88 | — | — | |
| SCHEMBL22176658 | 0.88 | — | — | |
| SCHEMBL335927 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024390-A | Cdc20 small molecule ligand compound and application of degradation agent thereof | 中国海洋大学 | 2023-11-10 | — | — | CN | claimed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | claimed |
| EP-4126839-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| EP-3172202-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Boehringer Ingelheim International GmbH (DE) | 2017-05-31 | — | — | EP | claimed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | claimed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | claimed |
| WO-2016014463-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | WO | claimed |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| CN-115443276-B | Pyridopyrimidinone derivatives and their use as arene receptor modulators | 东亚ST株式会社 | 2025-04-18 | — | — | CN | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4136088-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Dong-A ST Co., Ltd. (KR) | 2023-02-22 | — | — | EP | disclosed |
| EP-2041073-A1 | CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| EP-2040688-A1 | NEW CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20080171729-A1 | Use Of A Steroid For Enhancement Of Skin Permeability | NOVARTIS AG | 2008-07-17 | — | — | US | disclosed |
| WO-2008000410-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000409-A1 | NEW CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| EP-1773336-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | Novartis AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008092-A1 | USE OF A STEROID FOR ENHANCEMENT OF SKIN PERMEABILITY | NOVARTIS AG (CH) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ADCY9, ADCY7, GUCY1B1 | CHRM2 25/4885CHRM4 93/4885CHRM5 39/4885 |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | CHRM2 1616/4885CHRM4 1559/4885CHRM5 1896/4885 |
| US-12371431-B2 | Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor | BCL2L11, BCL2, BCL2L2 | CHRM2 4881/4885CHRM4 4885/4885CHRM5 4884/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | CHRM2 3588/4885CHRM4 3960/4885CHRM5 3534/4885 |
| US-20080171729-A1 | Use Of A Steroid For Enhancement Of Skin Permeability | SERPINA6, CYP11A1, HSD17B7 | CHRM2 3446/4885CHRM4 3119/4885CHRM5 3300/4885 |
| US-20250257064-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | BCL2, BAX, BCL2L2 | CHRM2 4877/4885CHRM4 4885/4885CHRM5 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.